INCA33890 Colorectal Cancer Study

This study aims to learn how adults with metastatic MSS colorectal cancer respond when INCA33890 is added to standard chemotherapy and Bevacizumab. MSS colorectal cancer responds differently to many therapies, making research into new combinations essential. Investigators are evaluating treatment response, tolerability, tumor activity, and how INCA33890 may influence clinical outcomes in the first‑line setting.

 

Disclaimer: This summary is for informational use only. It does not encourage enrollment or indicate that any investigational medication is effective or approved. Patients should consult their healthcare provider for individualized medical advice.